Safety pharmacology and the GI tract

Toxicology of the Gastrointestinal Tract

Volumn , Issue , 2007, Pages 53-80

  Jacoby, Henry I ^a  

^a Product Safety Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949271749     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Bass, A., Kinter, L., and Williams, P., Origins, practices and future of safety pharmacology. J. Pharmacol. Toxicol. Meth., 49, 145, 2004.
2. International Conference on Harmonization, M3 Timing of Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (FDA, 1997).
3. Guzmán, A., Safety pharmacology, pharmacokinetics and toxicology: an obstacle race in the development of a pharmaceutical compound. Meth. Findings Exp. Chem. Pharmacol., 25, Suppl. A, 2003.
4. Kinter, L.B. et al., Research overview status of safety pharmacology in the pharmaceutical industry, 1993. Drug Develop. Res., 32, 208, 1994.
5. Mattsson, J.L., Spencer, P.J., and Albee, R.R., A performance standard for clinical and functional observational battery examinations of rats. J. Amer. Col. Toxicol., 15, 239, 1996.
6. Irwin, S., Comprehensive observational assessment: a systematic, quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacologia (Berlin), 13, 222, 1968.
7. Haggerty, G.C., Strategies for and experience with neurotoxicity testing of new pharmaceuticals. J. Amer. Col. Toxicol., 10, 677, 1991.
8. Murphy, D.J., Safety pharmacology of the respiratory system: techniques and study design. Drug Develop. Res., 32, 237, 1994.
9. International Conference on Harmonization, S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (FDA, 1997).
10. Harrison, A.P. et al., Gastrointestinal tract models and techniques for use in safety pharmacology. J. Pharmacol. Toxicol. Meth., 49, 187, 2004.
11. Smith, S. et al., Novel techniques for testing of esophageal irritancy of liquids and tablets in dogs. Contemp. Top. Lab. Anim. Sci., 37, 66, 1998.
12. Peter, C.P., Handt, L.K., and Smith, S.M. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig. Dis. Sci., 43, 1998, 1998.
13. Lowe, C.E. et al., Upper gastrointestinal toxicity of alendronate. Am. J. Gastroenterol., 95, 634. 2000.
14. Borsch, G. and Schmidt, G., What’s new in steroid and nonsteroid drug effects on gastroduodenal mucosa? Pathol. Res. Pract., 180, 437, 1985.
15. Robert, A. and Nezamis, J.E., Histopathology of steroid-induced ulcers: an experimental study in the rat. Arch. Pathol., 77, 407, 1964.
16. Vane, J.R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231, 232, 1971.
17. Vane, J.R. and Botting, R.M., The mechanism of action of aspirin. Thromb. Res. 15, 255, 2003.
18. Whittle, B.J., Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology, 80, 94, 1981.
19. Kato, S. et al., Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J. Pharmacol. Exp. Ther., 303, 503, 2002.
20. Laudanno, O.M. et al., Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Acta Gastroenterol. Latinoam., 30, 27, 2000.
21. Takeuchi, K. et al., Analysis of pathogenic elements involved in gastric lesions induced by non-steroidal anti-inflammatory drugs in rats. J. Gastroenterol. Hepatol. 12, 36. 1997.
22. Liu, E.S. and Cho, C.H., Relationship between ethanol-induced gastritis and gastric ulcer formation in rats. Digestion, 62, 232, 2000.
23. Suwa, T. et al., Comparative studies on the gastrointestinal lesions caused by several nonsteroidal anti-inflammatory agents in rats. Agents Actions, 21, 167, 1987.
24. Fortun, P.J. and Hawkey, C.J., Nonsteroidal anti-inflammatory drugs and the small intestine. Curr. Opin. Gastroenterol., 21, 169, 2005.
25. Szabo, S., Mechanisms of mucosal injury in the stomach and duodenum: timesequence analysis of morphologic, functional, biochemical and histochemical studies. Scand. J. Gastroenterol. Suppl. 127, 2. 1987.
26. Brodie, D.A., Tate, C.L., and Hooke, K.F., Aspirin: intestinal damage in rats. Science, 9, 183, 1970.
27. Mariani, L., Factors influencing the indomethacin-induced intestinal lesions in the rat. Eur. J. Toxicol. Environ. Hyg., 8, 335, 1975.
28. Brodie, D.A. et al., Indomethacin-induced intestinal lesions in the rat. Toxicol. Appl. Pharmacol., 17, 615, 1970.
29. Fara, J.W. et al., Assessment and validation of animal models to evaluate topical effects of substances on gastrointestinal mucosa. Pharm. Res. 5, 165, 1988.
30. Spiller, R., Serotonergic modulating drugs for functional gastrointestinal diseases. Br. J. Clin. Pharmacol., 54, 11, 2002.
31. Friedel, D., Thomas, R., and Fisher, R.S., Ischemic colitis during treatment with alosetron. Gastroenterology, 120, 557, 2001.
32. Kamm, M.A., The complexity of drug development for irritable bowel syndrome. Aliment. Pharmacol. Ther., 16, 343, 2002.
33. Mullner, K. et al., Involvement of central K(ATP) channels in the gastric antisecretory action of 2-adrenoceptor agonists and beta-endorphin in rats. Eur. J. Pharmacol., 435, 225, 2002.
34. Kunchandy, J., Khanna. S., and Kulkarni, S.K., Effect of 2 agonists clonidine, guanfacine and B-HT 920 on gastric acid secretion and ulcers in rats. Arch. Int. Pharmacodyn. Ther., 275, 123, 1985.
35. Brodie, D.A. and Knapp, P.G., The mechanism of the inhibition of gastric secretion produced by esophageal ligation in the pylorus-ligated rat. Gastroenterology, 50, 787, 1966.
36. Komarov, S.A., Bralow, S.P., and Boyd, E., A permanent rat gastric fistula. Proc. Soc. Exp. Biol. Med., 112, 451, 1963.
37. Jacoby, H.I. et al., Antisecretory actions of aminophylline in the rat and dog. Digestion, 19, 237, 1979.
38. Setler, P.E. and Smith, G.P., Gastric emptying in rats with chronic gastric fistulas. Am. J. Dig. Dis., 14, 137, 1969.
39. de Rosalmeida, M.C. et al., Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. Dig. Dis. Sci., 48, 2064, 2003.
40. Miyasaka, K. et al., Enhanced gastric emptying of a liquid gastric load in mice lacking cholecystokinin-B receptor: a study of CCK-A, B, and AB receptor gene knockout mice. J. Gastroenterol., 39, 319, 2004.
41. Feldman, S. and Putcha, L., Effect of anti-Parkinsonism drugs on gastric emptying and intestinal transit in the rat. Pharmacology, 15, 503, 1977.
42. Lotti, V.J. et al., A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists. Life Sci., 39, 1631, 1986.
43. Gandia, P. et al., Influence of simulated weightlessness on the pharmacokinetics of acetaminophen administered by the oral route: a study in the rat. Fundam. Clin. Pharmacol., 18, 57, 2004.
44. Pu, H.F. et al., Effects of juice from Morinda citrifolia (Noni) on gastric emptying in male rats. Chin. J. Physiol., 47, 169, 2004.
45. Brodie, D.A., A comparison of anticholinergic drugs on gastric secretion, gastric emptying, and pupil diameter in the rat. Gastroenterology, 50, 45, 1966.
46. Jacoby, H.I. and Brodie, D.A., Gastrointestinal actions of metoclopramide: an experimental study. Gastroenterology, 52, 676, 1967.
47. Tabosa, A. et al., A comparative study of the effects of electroacupuncture and moxibustion in the gastrointestinal motility of the rat. Dig. Dis. Sci., 49, 602, 2004.
48. Yamano, M. et al., Effects of gastroprokinetic agents on gastroparesis in streptozotocin- induced diabetic rats. Naun. Schmied. Arch. Pharmacol., 356, 145, 1997.
49. Asai, T., Vickers, M.D., and Power, I., Clonidine inhibits gastric motility in the rat. Europ. J. Anaesth., 14, 316, 1997.
50. Matsuda, H. et al., Inhibitory mechanism of costunolide, a sesquiterpene lactone isolated from Laurus nobilis, on blood ethanol elevation in rats: involvement of inhibition of gastric emptying and increase in gastric juice secretion. Alcohol Alcoholism, 37, 121, 2002.
51. Macht, D.I., and Barba-Gose, J., Two new methods for pharmacological comparison of insoluble purgatives. J. Am. Pharm. Assoc. 20, 558, 1931.
52. Tan-No, K. et al., Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur. J. Pharm. Sci., 20, 357, 2003.
53. Ito, C. et al., Effect of GK-128 [2-[(2-methylimidazol-1-yl)methyl]-benzo[f]thiochromen-1-one monohydrochloride hemihydrate], a selective 5-hydroxytryptamine3 receptor antagonist, on colonic function in rats. J. Pharmacol. Exp. Ther., 280, 67, 1997.
54. Croci, T. and Bianchetti, A., Stimulation of faecal excretion in rats by 2-adrenergic antagonists. J. Pharm. Pharmacol., 44, 358, 1992.
55. Goldenberg, M.M., Honkomp, L.J., and Castellion, A.W., The antidiarrheal action of bismuth subsalicylate in the mouse and the rat. Am. J. Dig. Dis., 20, 955, 1975.
56. Awouters, F. et al., Loperamide antagonism of castor oil-induced diarrhea in rats:a quantitative study. Arch. Int. Pharmacodyn. Ther., 217, 29, 1975.
57. Riviere, P.J. et al., Prostaglandin E2-induced diarrhea in mice: importance of colonic secretion. Pharmacol. Exp. Ther., 256, 547, 1991.
58. Jacoby, H.I. and Lopez, I.A., Method for the evaluation of colonic propulsive motility in the mouse after ICV administered compounds. Dig. Dis. Sci. 29, 551, 1984.
59. Raffa, R.B., Mathiasen, J.R, and Jacoby, H.I., Colonic bead expulsion time in normal and mu-opioid receptor deficient (CXBK) mice following central (ICV) administration of µ- and -opioid agonists. Life Sci., 41, 2229, 1987.
60. Jacoby, H.I., Bonfilio, A.C. and Raffa, R.B., Central and peripheral administration of serotonin produces opposite effects on mouse colonic propulsive motility. Neurosci. Lett., 122, 122, 1991.
61. Raffa, R.B. and Jacoby, H.I., Effect of the Phe-D-Met-Arg-Phe-NH2-related peptides on mouse colonic propulsive motility: a structure-activity relationship study. J. Pharm. Exp. Ther. 254, 809, 1990.
62. Negri, L. et al., Effects of antisense oligonucleotides on brain delta-opioid receptor density and on SNC80-induced locomotor stimulation and colonic transit inhibition in rats. Br. J. Pharmacol., 128, 1554, 1999.
63. Martínez, V. et al., Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J. Physiol., 556, 221, 2004.
64. Radzievsky, A.A. et al., Single millimeter wave treatment does not impair gastrointestinal transit in mice. Life Sci., 71, 1763, 2002.
65. Osinski, M.A., Bass, P. and Gaumnitz, E.A., Peripheral and central actions of orphanin FQ (nociceptin) on murine colon. Am. J. Physiol. Gastrointest. Liver. Physiol. 276, G125, 1999.
66. Yamada, K. and Onoda, Y., Comparison of the effects of T-1815, yohimbine and naloxone on mouse colonic propulsion. J. Smooth Muscle Res. 29, 47, 1993.
67. King, G.L., Animal models in the study of vomiting. Can. J. Physiol. Pharmacol., 68, 260, 1990.
68. Selve, N. et al., Absence of emetic effects of morphine and loperamide in Suncus murinus. Eur. J. Pharmacol. 2, 256, 1994.
69. Marty, M., Chemotherapy-induced nausea and vomiting: from experimentation to experience. Bull. Cancer, 83,1014, 1996.
70. Naylor, R.J. and Rudd, J.A., Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Oncology, 53, Suppl. 1, 8, 1996.
71. Kinsella, T.J. et al., Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design. Clin. Cancer. Res., 6, 3670, 2000.
72. Enderlin, F.E. and Honohan, T., Long term bile collection in the rat. Lab. Anim. Sci., 27, 490, 1977.
73. Chipman, J.K. and Cropper, N.C., A technique for chronic intermittent bile collection from the rat. Res. Vet. Sci., 22, 366, 1977.
74. Gallo-Torres, H.E., Methodology for the determination of bioavailability of labeled residues. J. Toxicol. Environ. Health, 2, 827, 1977.
75. Balabaud, C. et al., Bile collection in free moving rats. Lab. Anim. Sci. 31, 273, 1981.
76. Tomlinson, P.W., Jeffery, D.J., and Filer, C.W., A novel technique for assessment of biliary secretion and enterohepatic circulation in the unrestrained conscious rat. Xenobiotica, 11, 863, 1981.
77. Rath, L. and Hutchison, M., A new method of bile duct cannulation allowing bile collection and re-infusion in the conscious rat. Lab. Anim., 23, 163, 1989.
78. Heitmeyer, S.A. and Powers, J.F., Improved method for bile collection in unrestrained conscious rats. Lab. Anim. Sci., 42, 312, 1992.
79. Cavarzan, A. et al., Action of intragastric ethanol on the pancreatic secretion of conscious rats. Digestion, 13, 145, 1975.
80. Colwell, A.R. Jr., Collection of pancreatic juice from rats and consequences of its continued loss. Am. J. Physiol., 164, 812, 1951.
81. Roze, C., Ling, N. and Florencio, H., Inhibition of gastric and pancreatic secretions by cerebroventricular injections of gastrin-releasing peptide and bombesin in rats. Regul. Pept., 3, 105, 1982.